Harkness Pharmaceuticals headquarters in Zug

Harkness Pharmaceuticals headquarters in Zug is both the imposing centre of the company and a physical expression of its power: a carefully softened corporate exterior gives way to layered security and restricted access. The complex draws together questions about confidential research, the supply of life-changing medication, and the company’s far-reaching nanobot programme, though not every thread is resolved inside the building itself.

Setting and Architecture

The headquarters stands on the outskirts of Zug as a large complex of blue steel and grey glass. Water reflects its towered roofline, while trees soften the scale of the site. A fountain stands in front, playing over a statue of two serpents entwined around a winged staff, a medical emblem whose promise of healing sits uneasily beside the company’s more troubling activities.

The grounds are presented as meticulously ordered as the architecture. From an elevated bridge between two blocks, Blake sees a car moving slowly through a vast, L-shaped car park and a groundskeeper mowing precise stripes into a lawn large enough for a herd of cattle. The expansive landscaping and reflective water lend the headquarters a composed, almost self-contained appearance: a corporate city set apart from its surroundings.

Research and Confidentiality

The headquarters is also a meeting place for questions about the company’s research workforce. Ingrid Denner had arranged to meet chief researcher Filippo Crosetti there on 14 June to discuss a separate issue, the contraindications position statement. She intended to use the meeting to press him about retained specialist contractor number 55, a forty-six-year-old British woman attached to his staff. Human resources would not disclose personal details, explaining that Crosetti required absolute confidentiality for specialists he personally recruited and supervised from the research facility in Locarno.

The distinction between the Zug headquarters and Crosetti’s research facility in Locarno matters: the scheduled meeting would bring an unresolved inquiry about confidential staff into the company’s central office, but the evidence does not establish that the meeting itself took place there. The headquarters thus marks an intended point of pressure in the investigation, where corporate administration and guarded research practices meet.

Entry and Security

When Blake, Jane Glasson, and Crosetti arrive by taxi, the building’s scale is matched by its controlled entry. At reception, Crosetti is recognized, while Jane’s identity is uncertain to the staff and Blake is an unknown visitor. Crosetti and Jane press their palms against a reader and receive passes to wear around their necks; Blake is photographed and issued a visitor pass marked GAST. The differing procedures make access visible as a hierarchy: familiarity and biometric registration for some, supervised visitor status for another.

The route inward continues through quiet lifts, connecting bridges, corridors, and successive sets of double doors. At the entrance to what Blake understands to be Harkness’s personal office, a large security guard refuses Crosetti immediate access. Jane speaks slowly and softly; the guard then calls into a lapel microphone, and a woman in a dark-blue trouser suit appears at the door. The scene shows that recognition by the company is not the same as unrestricted authority: even Crosetti must negotiate with the security system, while Jane’s controlled intervention changes the encounter.

Medicines and Corporate Reach

The headquarters gains significance beyond its walls through the products associated with Harkness Pharmaceuticals. In Holly Walsh’s home, Blake finds cartons of Ditrimantelline labelled as made in Switzerland and bearing the company’s name. Walsh has multiple sclerosis and says the experimental medicine has helped control her symptoms; she receives it through an anonymous benefactor calling herself Luscinia, who initially contacts her by email and claims to work in pharmaceuticals.

Walsh later tells Don Challenor that a private investigator working for some of Harkness’s creditors had asked about money from the Nightingale account at Credit Suisse. She suspects, but cannot confirm, that Luscinia may be a Harkness employee diverting company funds to pay for her treatment. The suspected connection makes the company’s medicines part of a financial and personal dependency: the drug has transformed Walsh’s experience of illness, while the anonymity and uncertain source of its funding leave her treatment vulnerable to events beyond her control.

The company’s reach is wider still. Jack Harkness explains that, over the preceding five years, nanobots have been included in Harkness Pharmaceuticals drugs and cosmetics, as well as in pesticides used on crops and antibiotics given to animals. Products named in that account include Elixtris and Fenextris, alongside headache remedies, antimalarials, and pain relief. The nanobots are absorbed through ingestion, injection, or the skin, and are continually replaced as production continues at factories around the world. The Zug headquarters therefore stands for an organization whose influence is not confined to its guarded offices: its products circulate through ordinary treatment and consumer use, while the purpose and consequences of the technology remain bound to the company’s larger plan.